Trend in and Correlates of Undergoing Radiotherapy in Taiwanese Cancer Patients' Last Month of Life

被引:0
|
作者
Hung, Yen-Ni [1 ,2 ]
Cheng, Skye Hung-Chun [3 ]
Liu, Tsang-Wu [4 ]
Chang, Wen-Cheng [5 ]
Chen, Jen-Shi [5 ]
Tang, Siew Tzuh [6 ,7 ]
机构
[1] Taipei Med Univ, Coll Nursing, Sch Gerontol Hlth Management, Taipei, Taiwan
[2] Taipei Med Univ, Coll Nursing, Master Program Long Term Care, Taipei, Taiwan
[3] Koo Fdn Sun Yat Sen Canc Ctr, Dept Radiat Oncol, Taipei, Taiwan
[4] Natl Hlth Res Inst, Natl Inst Canc Res, Taipei, Taiwan
[5] Chang Gung Mem Hosp Linkou, Div Hematol Oncol, Taoyuan, Taiwan
[6] Chang Gung Univ, Grad Sch Nursing, 259 Wen Hwa 1st Rd, Tao Yuan 333, Taiwan
[7] Chang Gung Mem Hosp Kaohsiung, Dept Nursing, 259 Wen Hwa 1st Rd, Tao Yuan 333, Taiwan
关键词
Radiotherapy; end-of-life care; population-based study; administrative data analysis; quality of end-of-life care; CELL LUNG-CANCER; PALLIATIVE RADIOTHERAPY; RADIATION-THERAPY; TREATMENT INTENSITY; METASTATIC CANCER; HEALTH LITERACY; END; CARE; QUALITY; AGGRESSIVENESS;
D O I
10.1016/j.jpainsymman.2016.03.011
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Context. A significant proportion of cancer patients at end of life (EOL) undergo radiotherapy, but this evidence is not from nationwide population-based studies. Objectives. The aims of this population-based study were to investigate the trend in undergoing radiotherapy among Taiwanese cancer patients' last month of life ( EOL radiotherapy) in 2001-2010 and to identify factors associated with EOL radiotherapy. Methods. This was a population-based retrospective cohort study analyzing data from Taiwan's national death registry, cancer registry, and National Health Insurance claims for EOL radiotherapy using multilevel generalized linear mixed modeling. Participants were Taiwanese cancer patients (N = 339,546) who died in 2001-2010. Results. Overall, 8.59% (7.97%-9.85%) of patients underwent EOL radiotherapy with a decreasing trend over time. Correlates of EOL radiotherapy included male gender, younger age, residing in less urbanized areas, diagnosis of lung cancer, metastatic disease, death within two years of diagnosis, and without comorbidities. Cancer patients were more likely to undergo EOL radiotherapy if they received primary care from medical oncologists and pediatricians, in a nonprofit, teaching hospital with a larger case volume of terminally ill cancer patients, and greater EOL care intensity. Conclusion. Approximately one-tenth of Taiwanese cancer patients underwent EOL radiotherapy with a decreasing trend over time. Undergoing EOL radiotherapy was associated with demographics, disease characteristics, physician specialty, and primary hospital's characteristics and EOL care practice patterns. Clinical and financial interventions should target hospitals/physicians that tend to aggressively treat at-risk cancer patients at EOL to carefully evaluate the appropriateness and effectiveness of using EOL radiotherapy. (C) 2016 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:395 / 403
页数:9
相关论文
共 50 条
  • [31] Longitudinal study of quality of life in patients with localized prostate cancer undergoing radiotherapy
    Monga, U
    Kerrigan, AJ
    Thornby, J
    Monga, TN
    Zimmermann, KP
    JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT, 2005, 42 (03) : 391 - 399
  • [32] Cancer Drug Use in the Last Month of Life in Men With Castration-Resistant Prostate Cancer
    Hu, Jason
    Aprikian, Armen G.
    Vanhuyse, Marie
    Dragomir, Alice
    JOURNAL OF ONCOLOGY PRACTICE, 2019, 15 (06) : 333 - +
  • [33] Longitudinal quality of life in Turkish patients with head and neck cancer undergoing radiotherapy
    Esra Citak
    Zeliha Tulek
    Supportive Care in Cancer, 2013, 21 : 2171 - 2183
  • [34] Quality of Life Outcomes for Bladder Cancer Patients Undergoing Bladder Preservation with Radiotherapy
    Michael A. Feuerstein
    Anuj Goenka
    Current Urology Reports, 2015, 16
  • [35] Quality of Life Outcomes for Bladder Cancer Patients Undergoing Bladder Preservation with Radiotherapy
    Feuerstein, Michael A.
    Goenka, Anuj
    CURRENT UROLOGY REPORTS, 2015, 16 (11)
  • [36] Population-based trends in systemic therapy use and cost for cancer patients in the last year of life
    Pataky, R. E.
    Cheung, W. Y.
    de Oliveira, C.
    Bremner, K. E.
    Chan, K. K. W.
    Hoch, J. S.
    Krahn, M. D.
    Peacock, S. J.
    CURRENT ONCOLOGY, 2016, 23 : S32 - S41
  • [37] Cross-linked hyaluronan gel improves the quality of life of prostate cancer patients undergoing radiotherapy
    Wilder, Richard B.
    Barme, Greg A.
    Gilbert, Ronald F.
    Holevas, Richard E.
    Kobashi, Luis I.
    Reed, Richard R.
    Solomon, Ronald S.
    Walter, Nancy L.
    Chittenden, Lucy
    Mesa, Albert V.
    Agustin, Jeffrey K.
    Lizarde, Jessica
    Macedo, Jorge C.
    Ravera, John
    Tokita, Kenneth M.
    BRACHYTHERAPY, 2011, 10 (01) : 44 - 50
  • [38] Chemotherapy and Tyrosine Kinase Inhibitors in the last month of life in patients with metastatic lung cancer: A patient file study in the Netherlands
    Mieras, Adinda
    Becker-Commissaris, Annemarie
    Pasman, H. Roeline W.
    Dingemans, Anne-Marie M. C.
    Kok, Edith, V
    Cornelissen, Robin
    Jacobs, Wouter
    van den Berg, Jan Willem
    Welling, Alle
    Bogaarts, Brigitte A. H. A.
    Pronk, Lemke
    Onwuteaka-Philipsen, Bregje D.
    EUROPEAN JOURNAL OF CANCER CARE, 2020, 29 (02)
  • [39] Active Anticancer Treatment During the Final Month of Life in Patients with Non-small Cell Lung Cancer
    Nieder, Carsten
    Tollali, Terje
    Dalhaug, Astrid
    Haukland, Ellinor
    Aandahl, Gro
    Pawinski, Adam
    Norum, Jan
    ANTICANCER RESEARCH, 2014, 34 (02) : 1015 - 1020
  • [40] A feasibility trial of acupuncture in cancer patients undergoing radiotherapy treatment
    Hughes, John
    Gyertson, Kylie
    Carballo, Lallita
    Plant, Hilary
    Sharman, Mitch
    Ruane, Katie
    Mendoza-Naranjo, Ariadna
    Hackshaw, Allan
    Cummings, Mike
    Edwards, Alex
    Lewith, George
    Fisher, Peter
    COMPLEMENTARY THERAPIES IN CLINICAL PRACTICE, 2021, 43